Purple Biotech Ltd. has announced a 1-for-10 reverse stock split, set to take effect on March 2, 2024. This decision, revealed on February 25, 2024, aims to adjust the number of shares held by shareholders following the market close on February 27, 2024. The reverse split is part of the company’s broader strategy to enhance its stock price and align with market expectations.
On Thursday, shares of PPBT opened at $0.52. The company’s stock has demonstrated volatility, with a fifty-day moving average price of $0.63 and a two-hundred-day moving average price of $0.86. Over the past year, the stock has experienced a low of $0.46 and a high of $3.07. Currently, Purple Biotech holds a market capitalization of $6.70 million, a price-to-earnings (P/E) ratio of -1.63, and a beta of 0.66.
Analyst Ratings and Institutional Investment
Analysts have largely expressed skepticism regarding Purple Biotech’s future. In a report dated December 29, 2023, Weiss Ratings maintained a “sell (e+)” rating for the stock. Additionally, Wall Street Zen downgraded the company to a “strong sell” on November 28, 2023. As of now, the consensus rating among investment analysts remains “Sell,” reflecting a cautious outlook on the company.
Despite the negative ratings, some institutional investors are still showing interest. Recently, SmartHarvest Portfolios LLC acquired a new stake in Purple Biotech during the fourth quarter, purchasing 47,454 shares valued at approximately $31,000. This acquisition indicates that institutional ownership currently stands at 9.64% of the total stock.
Company Overview and Future Prospects
Purple Biotech is a clinical-stage company focused on developing therapies to combat tumor immune evasion and drug resistance in cancer patients. Its oncology pipeline features several promising candidates. Notably, CM24 is a humanized monoclonal antibody in Phase 2 clinical trials aimed at treating pancreatic ductal adenocarcinoma. Another candidate, NT219, is undergoing Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck, as well as colorectal adenocarcinoma. Additionally, IM1240, a multi-valent antibody, is currently in preclinical stages.
As the reverse stock split approaches, the market will be closely watching Purple Biotech’s next moves and the potential impact on its stock performance and investor sentiment.
